C9067 HCPCS code: Gallium ga-68, dotatoc, diagnostic, 0.01 mci
C9067 is the HCPCS Level II code for gallium ga-68, dotatoc, diagnostic, 0.01 mci. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 500 per day on outpatient hospital claims.
Code details
| Field | Value |
|---|---|
| Section | C codes — Outpatient PPS (hospital outpatient temporary codes) |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 53 |
| BETOS category | O1E — Other drugs |
| Added | 2020-10-01 |
| Last action effective | 2025-01-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 500 | Prescribing Information |
| practitioner claims | 500 | Prescribing Information |
What changed for C9067
- 2020-10-01: C9067 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code C9067?
C9067 is the HCPCS Level II code for gallium ga-68, dotatoc, diagnostic, 0.01 mci. Short descriptor: "Gallium ga-68 dotatoc".
Does Medicare cover C9067?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
How many units of C9067 can be billed per day?
500 on outpatient hospital claims; 500 on practitioner claims (NCCI medically unlikely edits).
Related C90 codes
- C9014 — Injection, cerliponase alfa, 1 mg
- C9015 — Injection, c-1 esterase inhibitor (human), haegarda, 10 units
- C9016 — Injection, triptorelin extended release, 3.75 mg
- C9021 — Injection, obinutuzumab, 10 mg
- C9022 — Injection, elosulfase alfa, 1mg
- C9023 — Injection, testosterone undecanoate, 1 mg
- C9024 — Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
- C9025 — Injection, ramucirumab, 5 mg
- C9026 — Injection, vedolizumab, 1 mg
- C9027 — Injection, pembrolizumab, 1 mg
- C9028 — Injection, inotuzumab ozogamicin, 0.1 mg
- C9029 — Injection, guselkumab, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under C9067
- Watch C9067 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C9067
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.